Open-Access Plan in Europe Bans Publishing in Paywalled Journals

Research funding agencies in Europe will require grantees’ papers to be free to read when they are available online.

Written byAshley Yeager
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: Robert-Jan Smits, the Open Access Envoy of the European Commission, who helped spearhead Plan S
WIKIMEDIA, ARNO MIKKOR (EU2017EE)

Eleven European funding organizations announced today (September 4) an open-access initiative that requires grantees to make resulting research articles free to read as soon as they are published. The initiative is slated to begin in 2020.

“This will put increased pressure on publishers and on the consciousness of individual researchers that an ecosystem change is possible," Ralf Schimmer, head of the Scientific Information Provision at the Max Planck Digital Library in Munich, tells Science. The requirement, called Plan S, stipulates that researchers receiving funding from the agencies will not be permitted to publish in Nature, Science, Cell, The Lancet and other journals—totaling roughly 85 percent of scholarly publications—unless the journal publishers change their access policies.

“It is a very powerful declaration. It will be contentious and stir up strong feelings,” Stephen ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies